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OBJECTIVES This study was designed to determine whether simvastatin improves endothelial function in
children with familial hypercholesterolemia (FH).
BACKGROUND Endothelial function measured by flow-mediated dilation of the brachial artery (FMD) is
used as a surrogate marker of cardiovascular disease (CVD). Adult studies have shown that
statins reverse endothelial dysfunction and therefore reduce the risk for future CVD.
METHODS The study included 50 children with FH (9 to 18 years) and 19 healthy, non-FH controls.
Children with FH were randomized to receive simvastatin or placebo for 28 weeks. The
FMD was performed at baseline and at 28 weeks of treatment.
RESULTS At baseline, FMD was impaired in children with FH versus non-FH controls (p  0.024).
In the simvastatin FH group, FMD improved significantly, whereas the FMD remained
unaltered in the placebo FH group throughout the study period (absolute increase 3.9% 
4.3% vs. 1.2%  3.9%, p  0.05). In the simvastatin FH group, FMD increased to a level
similar to the non-FH controls (15.6%  6.8% vs. 15.5%  5.4%, p  0.958). Upon
treatment, the simvastatin FH group showed significant absolute reductions of total
cholesterol (TC) (2.16  1.04 mmol/l, 30.1%) and low-density lipoprotein cholesterol
(LDL-C) (2.13  0.99 mmol/l, 39.8%). The absolute change of FMD after 28 weeks of
therapy was inversely correlated to changes of TC (r  0.31, p  0.05) and LDL-C
(r  0.31, p  0.05).
CONCLUSIONS Our data show significant improvement of endothelial dysfunction towards normal levels after
short-term simvastatin therapy in children with FH. These results emphasize the relevance of
statin therapy in patients with FH at an early stage, when the atherosclerotic process is still
reversible. (J Am Coll Cardiol 2002;40:2117–21) © 2002 by the American College of
Cardiology Foundation
Familial hypercholesterolemia (FH) is an inherited autoso-
mal dominant disorder of lipoprotein metabolism caused by
a plethora of mutations in the low density lipoprotein
(LDL) receptor gene (1). With a frequency of one in 400
persons, FH is one of the most common inborn errors of
metabolism in the Dutch population (2). This disorder is
associated with elevated levels of LDL cholesterol (LDL-C)
and premature atherosclerosis, although the disease is usu-
ally asymptomatic in children (3).
See page 2122
Endothelial dysfunction is an early reversible stage in the
development of atherosclerosis (4) and has predictive value
for future cardiovascular events (5,6). It is characterized by
an imbalance in favor of proatherogenic factors such as
vasoconstriction, platelet activation, monocyte adhesion,
thrombogenesis, and inflammation (7). In the past decade,
a number of studies have shown that endothelial function
measured as flow-mediated dilation (FMD) is impaired in
children with FH (8–10). Hydroxymethylglutaryl coenzyme
A reductase inhibitors (statins) have been shown to reverse
endothelial dysfunction; but only in adult dyslipidemic
patients (11–13). However, at later stages statin therapy is
unable to normalize endothelial function in coronary arter-
ies, likely because of structural changes.
In spite of the aggressive nature of FH, the recommended
therapy for children consists of a cholesterol-lowering diet
and, if deemed necessary, bile-acid binding resins (14). The
use of statins in children has been evaluated to a certain
degree, but is still under debate (15–17). In view of the
limited timespan for cardiovascular prevention in patients
with FH, improvement of endothelial function at an early
reversible stage of the atherosclerotic process would provide
a strong argument for implementation of statin therapy in
childhood (4).
This placebo-controlled study was designed to evaluate
the effect of simvastatin therapy on endothelial function in
children with FH. At baseline, endothelial function was
assessed as FMD of the brachial artery, a parameter for
endothelium-dependent vasodilatation, in children with FH
(n  50) and non-FH controls (n  19). In the children
with FH, the measurements were repeated after 28 weeks of
simvastatin (n  28) or placebo (n  22) therapy, respec-
tively.
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PATIENTS AND METHODS
Patients. A total of 50 heterozygous children with FH,
ages nine to 18, were randomized to receive either simva-
statin or placebo at a 3:2 ratio, respectively. Twenty-eight
children were randomized to simvastatin and 22 to placebo.
Nineteen healthy, non-FH siblings between nine and 18
years of age participated in the study as controls. The
following criteria were designed to select children with
heterozygous FH: plasma LDL-C levels above 95th per-
centile for age and gender, a documented family history of
hyperlipidemia with LDL-C levels above the 95th percen-
tile for age and gender before treatment, or a personal
diagnosis of FH by detection of a mutation in the LDL
receptor gene. Exclusion criteria were smoking, current use
of any vasoactive medications, and concomitant conditions
such as serious illness, hypertension, or diabetes mellitus.
Study design. The dosage of simvastatin was doubled every
eight weeks from 10 to 20 to 40 mg per day. The assessment
of FMD of the brachial artery as parameter for
endothelium-dependent vasodilation was performed at
baseline (at entry of the study) and after 28 weeks of
treatment (40 mg of simvastatin or placebo). Total serum
cholesterol (TC), triglycerides (TG), LDL-C, and high-
density lipoprotein cholesterol (HDL-C) were measured at
both visits. Total cholesterol and TG were analyzed by
enzymatic methods on a Hitachi 747 analyzer as previously
described (18). High density lipoprotein cholesterol was
isolated with heparin-2M manganese chloride (19). Safety
measurements including hepatic transaminases (alanine
aminotransferase [ALT] and aspartate aminotransferase
[AST]) and creatine kinase (CK) were measured during
each visit. Physical examination (height, weight, blood
pressure) was performed during the first and the last visit.
Each child or child’s parents gave written informed consent
for his or her participation in the study, which was approved
by the Institutional Review Board of the Academic Medical
Center (Amsterdam).
Flow-mediated dilation. The assessment of FMD was
performed as published previously (20,21). In summary, all
measurements were performed during the morning in a
fasting state. All children refrained from alcohol and
caffeine-containing beverages. Patients were studied in su-
pine position. The blood pressure cuff was placed just below
the elbow of the right arm. After a 10 to 15 min rest, the
brachial artery in the right antecubital fossa was visualized
using a 7.5 MHz transducer (5,22). After an optimal image
of the brachial artery wall was obtained, a wall tracking
system was used to measure the lumen diameter. After two
baseline vessel diameter measurements were obtained, reac-
tive hyperemia was induced by inflating the blood pressure
cuff to 200 mm Hg distal to the location of transducer.
Upon release of the cuff after 4 min, the ensuing dilation of
the brachial artery is predominantly mediated by endothelial
NO release (23). Ultrasonography then continued for 5 min
to allow for lumen diameter measurements at 20-s intervals.
Wall track measurements were stored digitally and analyzed
offline using the wall track system software analysis package
(24). All measurements were performed by the same ob-
server, unaware of clinical details and the stage of the
experiment. Baseline vessel diameter was calculated as the
average of two measurements. Flow-mediated dilation was
calculated at each examination as ([maximal lumen diameter
after ischemia diameter at baseline]/diameter at baseline)
and expressed as a percentage (25). Intra- and intersession
variation coefficients were 1.1% and 3.8% respectively (21).
The total duration of this investigation was approximately
20 min.
Statistical analysis. Analyses were performed using SPSS
10.0 for Windows software. The baseline characteristics of
the controls versus the treatment and placebo group were
compared by analysis of variance. In case of a significant
result a post hoc analysis was performed. Multiple compar-
isons were taken into account by using the Bonferroni
method. Differences between two groups were tested by
using Student t test for continuous data. Skewed data were
log-transformed before testing. Mean values before and
after therapy were compared using the paired sample t test.
Correlations were tested by using the bivariate Pearson
correlation test for continuous variables. A p value 0.05
was considered statistically significant.
RESULTS
Baseline characteristics showed no significant difference
with regard to gender, age, body mass index (BMI), blood
pressure, and baseline vessel size between the non-FH
control group, placebo FH group, and simvastatin FH
group (Table 1). However, TC and LDL-C were signifi-
cantly higher in the children with FH compared with the
non-FH controls (p 0.0001). Flow-mediated dilation was
impaired in the children with FH versus the non-FH
controls (p  0.024). There were no significant differences
with regard to age, gender, BMI, and blood pressure
between the simvastatin FH and placebo FH group. Also,
lipid profile, baseline vessel size, and FMD were not
significantly different between these two groups.
After 28 weeks, the FMD increased significantly in the
simvastatin FH group (p  0.0001). In the placebo FH
Abbreviations and Acronyms
ALT  alanine aminotransferase
AST  aspartate aminotransferase
BMI  body mass index
CK  creatine kinase
CVD  cardiovascular disease
FH  familial hypercholesterolemia
FMD  flow-mediated dilation
HDL-C  high-density lipoprotein cholesterol
LDL-C  low-density lipoprotein cholesterol
TG  triglycerides
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group, FMD remained unaltered throughout the study
period (Fig. 1). There was no difference with regard to the
baseline vessel sizes between both groups at 28 weeks
(simvastatin: 2.96  0.53 mm; placebo: 3.05  0.38 mm, p
 0.592). The mean absolute change in FMD was signif-
icantly higher in the simvastatin FH group compared with
the placebo FH group (3.9%  4.3% vs. 1.2%  3.9%, p 
0.05). Eight children in the placebo FH group (8/22; 36%),
compared with 19 children in the simvastatin FH group
(19/28; 68%), had an improvement of FMD 2.5%. In the
simvastatin FH group, FMD increased to a level similar to
that in non-FH controls (15.6%  6.8% vs. 15.5%  5.4%,
p  0.958).
After 28 weeks of treatment there was a significant mean
absolute reduction of TC (2.16  1.04 mmol/l, p 
0.0001), LDL-C (2.13  0.99 mmol/l, p  0.0001) and
TG (0.19  0.37 mmol/l, p  0.002) in the simvastatin
FH group (Table 2). These data match with a TC reduction
of 30.1%, a LDL-C reduction of 39.8% and a TG reduction
of 16.7%. There was an absolute increase in HDL-C (4.5%)
in the simvastatin FH group; however, the change did not
reach statistical significance. There were no significant
changes in lipoproteins in the placebo FH group compared
to baseline. The mean absolute changes for TC, LDL-C,
and TG were significantly higher in the simvastatin FH
group than in the placebo FH group. Except for LDL-C,
the lipoproteins in the simvastatin FH group after 28 weeks
were reduced to levels comparable to those of the non-FH
control group. There were no significant differences with
regard to safety measurements (ALT, AST, and CK)
between simvastatin and placebo FH groups and no adverse
events were reported (data not shown).
In the children with FH the change of FMD after 28
weeks of therapy was inversely correlated to absolute
changes of TC (r   0.31, p  0.05) and LDL-C
(r  0.31, p  0.05).
DISCUSSION
Our data clearly show that children with FH are character-
ized by impaired endothelial function. More importantly,
we demonstrate a significant improvement of endothelial
dysfunction in children with FH after short-term statin
therapy.
Patients with FH are characterized by severely increased
LDL-C levels, a major risk factor for premature atheroscle-
rosis, and show symptoms of cardiovascular disease (CVD)
at relatively young age, sometimes even before the age of 30
(1). Several population studies have demonstrated that, in
the general population, the process of atherosclerosis begins
in adolescence (26,27). In view of the aggressive nature of
CVD in adult patients with FH, it is safe to assume that in
these individuals atherosclerotic changes already begin in
early childhood (3,26). In line, several reports have demon-
strated the presence of endothelial dysfunction in children
with FH (8–10), which clearly precedes the onset of
morphological changes (28). In the present study, we
verified the presence of endothelial dysfunction in children
Figure 1. Flow-mediated dilation (FMD) (%) placebo versus simvastatin
(familial hypercholesterolemia [FH]) at baseline and 28 weeks. Striped bar
 baseline; white bar  28 weeks. *p  0.0001 vs. baseline; †p  0.05, 
FMD placebo vs.  FMD simvastatin.
Table 1. Baseline Characteristics of the FH Children and Controls
Controls
(Non-FH)
n  19
Simvastatin
(FH)
n  28
Placebo
(FH)
n  22 p Value
No (%) male 11 (58) 15 (54) 11 (50)
Age (yrs) 14.2  3.1 14.6  2.0 14.6  2.5 0.826
BMI 21.5  5.4 21.1  3.7 21.5  4.0 0.943
Systolic blood pressure (mm Hg) 121  17 125  14 125  17 0.592
Diastolic blood pressure (mm Hg) 66  11 66  9 67  8 0.988
TC (mmol/l) 4.32  0.85 6.97  1.24* 7.34  1.44* 0.0001
HDL-C (mmol/l) 1.42  0.31 1.27  0.22 1.40  0.30 0.148
LDL-C (mmol/l) 2.51  0.66 5.31  1.14* 5.47  1.44* 0.0001
Triglycerides (mmol/l)† 0.76 (0.50–1.38) 0.79 (0.50–1.82) 1.07 (0.34–1.79) 0.222
Baseline vessel size (mm) 3.10  0.53 3.19  0.59 3.14  0.41 0.769
FMD (%) 15.6  6.8 11.7  5.0* 11.6  3.5* 0.024
All values are given as means (SD) except for triglycerides given as median (range).
BMI  body mass index; FH  familial hypercholesterolemia; FMD  flow-mediated dilation; HDL-C  high-density
lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; TC  total cholesterol; *post hoc analyses p  0.05, vs
controls; †tested after log-transformation.
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with FH without signs of macrovascular disease as com-
pared with age and non-FH controls.
After short-term (28 weeks) statin therapy we show an
improvement of endothelial dysfunction in the hypercho-
lesterolemic children. To the best of our knowledge, this is
the first placebo-controlled trial that assessed the effects of
statin therapy on endothelial function in children with FH.
Many researchers investigated the effect of cholesterol-
lowering therapy on peripheral (11,13) and coronary endo-
thelial function (29–32), albeit in adults. Both positive
(11,29–31) and negative (32) results have been reported.
We have previously demonstrated complete reversibility of
peripheral endothelial dysfunction in adult patients with FH
after short-term lipid-lowering therapy (11). In contrast,
after long-term statin therapy in patients with coronary
artery disease, clear attenuation of the acetylcholine-induced
“paradoxical” vasoconstriction has been demonstrated, but
endothelium-dependent vasodilation could not be restored
(30,31). These findings emphasize that in order to achieve
normalization of endothelial function in “atherogenic” vas-
cular beds, such as the coronary arteries, therapy should be
initiated at an early stage, before the onset of severe
macrovascular structural abnormalities.
In our study, the obtained reductions for TC, LDL-C,
and TG are comparable to those in adults (33). Previous
statin trials in children showed similar reductions in lipids,
but these studies contained small numbers or included only
boys (15–17). In the present cohort, no toxicity or serious
adverse or side effects were reported by the children during
the course of this study. However, the duration of the
present study is too short to draw conclusions with regard to
the safety of long-term use of simvastatin in children. The
long-term safety and efficacy of statins in children is
currently being evaluated in ongoing trials at our depart-
ment.
The mechanism behind the beneficial effects of simvasta-
tin on endothelial function can be twofold: 1) by the
inhibition of hepatic HMG CoA reductase and the subse-
quent lowering of serum cholesterol levels (34), or 2) by a
direct effect on the vascular wall (35). The correlation
between FMD improvement and the degree of LDL
cholesterol lowering in the current study implies a role for
cholesterol lowering per se in mediating the beneficial
effects of statins. However, evidence has cumulated to show
that statins also exert lipid-independent pleiotropic effects
on the vasculature; for instance, by upregulating endothelial
cell NO synthase through stabilization of messenger ribo-
nucleic acid levels. In this respect, it remains to be estab-
lished whether and to what extent non-statin-induced lipid
lowering will have similar effects on vascular reactivity.
Finally, it should be taken into account that changes in
vascular smooth muscle cell reactivity cannot be excluded as
a potential cause of the altered FMD response, as nitroglyc-
erin was not administered to these young children. How-
ever, in previous studies we and others have shown normal
vascular responses towards exogenous nitrates in hypercho-
lesterolemia (8,11), making it unlikely that altered smooth-
muscle cell reactivity is of relevance in the present study.
Clinical implications. Endothelial dysfunction represents
one of the earliest stages of atherogenesis and has been
shown to have a clear predictive value for future CVD. In
the present study, we show an improvement of endothelial
dysfunction in the forearm vasculature after short-term
statin therapy in children with FH. These findings under-
score the importance of lipid-lowering therapy in children
with FH. Hence, until long-term safety data on the use of
statins in children become available, the current data vigor-
ously support the institution of statin therapy at early stages,
when endothelial dysfunction is still amenable to complete
normalization.
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Table 2. Lipid Measurements at Baseline, 28 Weeks, and Mean Absolute Change From
Baseline for the Simvastatin and Placebo FH Group*
Baseline 28 Weeks p Value* Absolute Change p Value†
TC (mmol/l)
Simvastatin 6.97  1.24 4.80  1.05 0.0001 2.16  1.04 0.0001
Placebo 7.34  1.44 7.31  0.33 0.854 0.05  1.17
HDL-C (mmol/l)
Simvastatin 1.27  0.22 1.32  0.24 0.141 0.05  0.17 0.080
Placebo 1.40  0.30 1.34  0.33 0.300 0.05  0.22
LDL-C (mmol/l)
Simvastatin 5.31  1.14 3.17  0.96 0.0001 2.13  0.99 0.0001
Placebo 5.47  1.44 5.45  2.03 0.819 0.05  1.06
Triglycerides (mmol/l)‡
Simvastatin 0.79 (0.50–1.82) 0.60 (0.30–1.65) 0.002 0.19  0.37 0.041
Placebo 1.07 (0.34–1.79) 0.80 (0.40–2.55) 0.791 0.10  0.54
*Lipids baseline vs. 28 weeks, †absolute change simvastatin vs. placebo; ‡tested after log-transformation. All values are given as
means (SD) except for triglycerides given as median (range).
FH  familial hypercholesterolemia; HDL-C  high density lipoprotein cholesterol; LDL-C  low density lipoprotein
cholesterol; TC  total cholesterol.
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